secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2026-10-14T11:21:15+00:00
Accession:  0001398733-26-000056
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Aquestive licenses LIBERVANT seizure-cluster film to Eton for $10M upfront, up to $47.5M milestones
--------------------------------------------------------------------------------

- Aquestive received a $10.0M upfront license fee from Eton for exclusive U.S. rights to LIBERVANT (diazepam) buccal film for epilepsy seizure clusters.
- Up to $47.5M milestones: $10M at first U.S. commercial sale (cut to $5M absent full FDA approval for ages 2-5), $2.5M for ages 6-11, $35M on net sales.
- Aquestive also gets mid-teens royalties on U.S. net sales and serves as exclusive manufacturer under a 20-year supply agreement.
- LIBERVANT holds FDA tentative approval; full approval for ages 12+ expected after VALTOCO orphan exclusivity lapses Jan 10, 2027; launch targeted April 2027.
- Type 9 NDA to add ages 6-11 has a PDUFA date of March 29, 2027; U.S. seizure rescue market exceeds $450M annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000056/0001398733-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000056/aqst-20261013.htm
  HTML page:      https://secwatch.observer/filing/0001398733-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer